Ligand-modified nanocarriers for oral drug delivery: Challenges, rational design, and applications
文献类型：期刊论文
| 作者 | Zhang, Yaqi2,3; Wang, Yaying2,3; Li, Xiang2,3; Nie, Di2,3; Liu, Chang2,3; Gan, Yong1,2,3
|
| 刊名 | JOURNAL OF CONTROLLED RELEASE
 |
| 出版日期 | 2022-12-01 |
| 卷号 | 352页码:813-832 |
| ISSN号 | 0168-3659 |
| 关键词 | Ligand-modified nanocarriers Transcytosis Transporter Active targeting Oral drug delivery Local drug delivery |
| DOI | 10.1016/j.jconrel.2022.11.010 |
| 通讯作者 | Gan, Yong(ygan@simm.ac.cn) |
| 英文摘要 | Ligand-modified nanocarriers (LMNCs) specific to their targets have attracted increasing interest for enhanced oral drug delivery in recent decades. Although the design of LMNCs for enhanced endocytosis and improved exposure of the loaded drugs through the oral route has received abundant attention, it remains unclear how the design influences their transcellular process, especially the key factors affecting their functions. This review discusses the extracellular and cellular barriers to orally administered LMNCs in the gastrointestinal (GI) tract and new discoveries regarding the GI protein corona and the sequential transport barriers that impede the preplanned movements of LMNCs after oral administration. Furthermore, innovative progress in considering key factors (including target selection, ligand properties, and other important factors) in the rational design of LMNCs for oral drug delivery is presented. In particular, some factors that endow LMNCs with efficient transcytosis rather than only endocytosis are highlighted. Finally, the prospects of orally administered LMNCs in disease therapy for the enhanced oral/local bioavailability of active pharmaceutical ingredients, as well as emerging delivery routes, such as lymphatic drug delivery and systemic location-specific drug release based on oral transcellular LMNCs, are discussed. |
| WOS关键词 | SOLID LIPID NANOPARTICLES ; MEDIATED ENDOCYTOSIS ; DOCETAXEL DELIVERY ; PROTEIN CORONA ; MUCUS BARRIER ; LINKER SIZE ; IN-VITRO ; BINDING ; ABSORPTION ; TRANSPORT |
| 资助项目 | National Science Fund for Distinguished Young Scholars[82025032] ; Major International Joint Research Project of Chinese Academy of Sciences[153631KYSB20190020] ; Key Research Program of Chinese Academy of Sciences[ZDBS-ZRKJZ-TLC005] ; National Key Research and Development Program of China[2020YFE0201700] ; Shanghai Municipal Science and Technology Major Project[TM202101L003] |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| 出版者 | ELSEVIER |
| WOS记录号 | WOS:001069665100002 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/307137]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Gan, Yong |
| 作者单位 | 1.Natl Inst Food & Drug Control, NMPA Key Lab Qual Res & Evaluat Pharmaceut Excipi, Beijing 100050, Peoples R China 2.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhang, Yaqi,Wang, Yaying,Li, Xiang,et al. Ligand-modified nanocarriers for oral drug delivery: Challenges, rational design, and applications[J]. JOURNAL OF CONTROLLED RELEASE,2022,352:813-832. |
| APA | Zhang, Yaqi,Wang, Yaying,Li, Xiang,Nie, Di,Liu, Chang,&Gan, Yong.(2022).Ligand-modified nanocarriers for oral drug delivery: Challenges, rational design, and applications.JOURNAL OF CONTROLLED RELEASE,352,813-832. |
| MLA | Zhang, Yaqi,et al."Ligand-modified nanocarriers for oral drug delivery: Challenges, rational design, and applications".JOURNAL OF CONTROLLED RELEASE 352(2022):813-832. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。